For a pdf copy of my complete CV, click here.

Academic Positions

Harvard Medical School
Co-Director of Research Ethics, Center for Bioethics (2018- )
Faculty, Center for Bioethics (2015- )

Brigham and Women’s Hospital
Research Scientist, Department of Medicine (2017- )
Research Fellow, Department of Medicine (2015-2017)

Boston University
Visiting Researcher, Center for Philosophy and History of Science (2015- )

McGill University
Research Fellow, Biomedical Ethics Unit (2012-2015)
Instructor, Department of Philosophy (2015)


Ph.D. Philosophy, University of Western Ontario (2012)

M.A. Philosophy, University of Western Ontario (2006)

B.A. (Honors) Philosophy, University of Illinois at Chicago (2004)

Research Support

Canadian Institutes of Health Research, Project Grant (2017-2021)
Co-investigator, “Developing a Framework for the Ethical Design and Conduct of Pragmatic Trials

Laura and John Arnold Foundation (2017-2020)
Principal Investigator, “Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium

Canadian Institutes of Health Research, Project Grant (2016-2020)
Co-investigator, “Ethics, Efficiency, and Patient Burden in Drug Development”

Recent Publications

Hey SP, Kesselheim AS (2018). Defining “True and Non-Misleading” for Pharmaceutical Promotion. The Journal of Law, Medicine & Ethics 46(2):552-4.

Hey SP (2018). Reducing Research Waste: What Can IRBs Do To Help? Harvard Medical School Bioethics Journal.

Gyawali B, Hey SP, Kesselheim AS (2018). A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. JAMA Network Open 1(2):e180416.

Hey SP (2018). Is Informed Consent for Biomedical Research a Fair Exchange? The Spoke June 13.

Horn AR, Weijer C, Hey SP, Brehaut J, Fergusson DA, Goldstein CE, Grimshaw J, Taljaard M (2018). Thinking Clearly About The FIRST Trial: Addressing Ethical Challenges in Cluster Randomised Trials of Policy Interventions Involving Health Providers. Journal of Medical Ethics doi: 10.1136/medethics-2017-104282.

Hey SP, Weijer C, Taljaard M, Kesselheim AS (2018). Research Ethics for Emerging Trial Designs: Does Equipoise Need to Adapt? BMJ 360:k226.

Hey SP, London AJ, Weijer C, Rid A, Miller F (2017). Is The Concept of Clinical Equipoise Still Relevant to Research? BMJ 359:j5787.

Hey SP (2017). Ethical Challenges in Biomarker-Driven Drug Development. Clinical Pharmacology & Therapeutics 103:23-25.

Hey SP, Cohen IG, Adashi EY, Kesselheim AS (2017). Influence, Integrity, and the FDA: An Ethical FrameworkScience 357(6354):876-877.

Hey SP, Franklin JM, Avorn J, Kesselheim AS (2017). Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein InhibitorsCirculation: Cardiovascular Quality and Outcomes 10(6):e003121.

Hey SP (2017). Clinical Trial Participants Should Have A Say in New Drug Pricing. STAT News, May 18.

Hey SP & Barsanti-Innes B (2017). Epistemology, Ethics, and Progress in Precision Medicine. Perspectives in Biology and Medicine 59(3):293-310.

Hey SP & Kesselheim AS (2017). Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations. Hastings Center Report 47(2):16-20.

Hey SP (2017). Priority, Prediction and the Ethical Research Enterprise. Journal of Medical Ethics 43(12):812-813.

Barsanti-Innes B, Hey SP, & Kimmelman J (2017). The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic TestingThe Oncologist 22(1):89-96.

See Google Scholar for the full list and links to publications.

Recent Presentations

“Informed Consent and Innovative Trial Designs.” Annual Society for Clinical Trials Meeting, Portland, OR; May 2018.

“Draft Ethical Framework for the Design and Conduct of Pragmatic Trials.” National Institutes of Health, Embedded Pragmatic Clinical Trials of Therapeutic A vs. B Interventions Conference. Bethesda, MD; May 2018.

“Improving Research Ethics and Oversight with Interactive Data Visualization.” College of the Holy Cross, Worcester, MA; April 2018.

“Visualizing Clinical Research Portfolios.” Research Ethics Consortium, Harvard Medical School; November 2017.

“Assay Validation and Ethical Challenges in Precision Medicine: A Case Study of BRAF Mutation Testing in Metastatic Melanoma.” Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital; September 2017.

“Precision Medicine and Pragmatic Trials: Friends or Foes?” Annual Society for Clinical Trials Meeting, Liverpool, UK; May 2017.

“Ethical Considerations in Pragmatic Cluster Randomized Trials.” Research Ethics Consortium, Harvard Medical School; February 2017.